Can a new drug work safely in patients with kidney failure?

NCT ID NCT07763418

Not yet recruiting Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study looks at how the experimental drug golcadomide is processed by the body in people with severe kidney impairment or end-stage renal disease compared to those with normal kidney function. The goal is to understand how kidney function affects drug levels and safety after a single dose. Participants will receive one dose of golcadomide, and researchers will measure drug concentrations in the blood and monitor for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: golcadomide (BMS-986369), an experimental drug
What this could lead to: If successful, this could help determine safe dosing of golcadomide for patients with kidney problems, potentially expanding treatment options.
What could go wrong: This is an early-phase study with a small number of participants, so results may not apply broadly. The drug may behave differently in real-world patients, and safety risks remain unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY FAILURE, CHRONIC

Contacts and locations

Locations

Local Institution - 0001

Orlando, Florida, 32809-3017, United States
Local Institution - 0002

Miami Lakes, Florida, 33014, United States
Local Institution - 0003

Chandler, Arizona, 85225, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.